The effect of Celecoxib on depression in patients with COVID-19

Phase 2

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20090117001556N142
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age between 18 to 60 years
At least 20 days after the onset of symptoms and 7 days after the last day the patient was symptomatic, the patient should show a score of 14-17 on HDRS (moderate depression)

Exclusion Criteria

History of depression before infected with COVID-19
Psychosis
Any other mental disorder in another axis
Taking other psychiatric drugs which can alter cognitive functions
History of ECT in recent two months
Thyroid dysfunctions
Kidney disease
Liver disease
History of cognitive dysfunction or dementia
Pregnant or lactating women
Serious suicidal thoughts (<2 in suicidal HDRS section)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of Depression. Timepoint: by Hamilton Depression Rating Scale (HDRS). Method of measurement: Baseline and weeks 3 and 6.